Trident Texofab [TTFL] vs Indo Count [ICIL] Detailed Stock Comparison
Trident Texofab
BSE
Loading...
Indo Count
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Trident Texofab wins in 3 metrics, Indo Count wins in 15 metrics, with 0 ties. Indo Count appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Trident Texofab | Indo Count | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 103.29 | 18.79 | Indo Count |
| Price-to-Book Ratio | 4.64 | 2.03 | Indo Count |
| Debt-to-Equity Ratio | 62.67 | 63.61 | Trident Texofab |
| PEG Ratio | N/A | 24.01 | N/A |
| EV/EBITDA | 44.92 | 11.39 | Indo Count |
| Profit Margin (TTM) | 2.06% | 5.93% | Indo Count |
| Operating Margin (TTM) | 2.47% | 4.62% | Indo Count |
| EBITDA Margin (TTM) | 2.47% | 4.62% | Indo Count |
| Return on Equity | 7.91% | 11.27% | Indo Count |
| Return on Assets (TTM) | 2.62% | 6.69% | Indo Count |
| Free Cash Flow (TTM) | $-137.08M | $1.43B | Indo Count |
| Dividend Yield | N/A | 0.86% | N/A |
| 1-Year Return | 384.01% | -39.98% | Trident Texofab |
| Price-to-Sales Ratio (TTM) | 2.64 | 1.15 | Indo Count |
| Enterprise Value | $2.46B | $58.31B | Indo Count |
| EV/Revenue Ratio | 2.01 | 1.40 | Indo Count |
| Gross Profit Margin (TTM) | 14.02% | 50.59% | Indo Count |
| Revenue per Share (TTM) | $116 | $210 | Indo Count |
| Earnings per Share (Diluted) | $2.08 | $12.42 | Indo Count |
| Beta (Stock Volatility) | -1.45 | -0.08 | Trident Texofab |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Trident Texofab vs Indo Count Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Trident Texofab | 0.73% | 0.35% | -0.39% | 12.43% | 30.09% | 25.24% |
| Indo Count | -3.27% | -10.45% | -20.41% | -26.58% | -18.58% | -31.90% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Trident Texofab | 384.01% | 79.12% | 414.00% | 397.34% | 397.34% | 397.34% |
| Indo Count | -39.98% | 64.95% | 267.85% | 31.60% | 7,527.45% | 2,607.66% |
Performance & Financial Health Analysis: Trident Texofab vs Indo Count
| Metric | TTFL | ICIL |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.22B | ₹47.94B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 6,700 | 228,047 |
| 90 Day Avg. Volume | 18,958 | 292,307 |
| Last Close | ₹214.85 | ₹233.40 |
| 52 Week Range | ₹42.01 - ₹220.00 | ₹213.55 - ₹438.90 |
| % from 52W High | -2.34% | -46.82% |
| All-Time High | ₹220.00 (Jun 23, 2025) | ₹450.65 (Jul 01, 2024) |
| % from All-Time High | -2.34% | -48.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.27% | -0.07% |
| Quarterly Earnings Growth | 0.27% | -0.88% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.06% |
| Operating Margin (TTM) | 0.02% | 0.05% |
| Return on Equity (TTM) | 0.08% | 0.11% |
| Debt to Equity (MRQ) | 62.67 | 63.61 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹46.27 | ₹115.00 |
| Cash per Share (MRQ) | ₹3.09 | ₹12.16 |
| Operating Cash Flow (TTM) | ₹-137,076,992 | ₹3.94B |
| Levered Free Cash Flow (TTM) | ₹-188,124,000 | ₹-687,299,136 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.86% |
| Last 12-Month Dividend | ₹0.00 | ₹2.00 |
Valuation & Enterprise Metrics Analysis: Trident Texofab vs Indo Count
| Metric | TTFL | ICIL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 103.29 | 18.79 |
| Forward P/E | N/A | 24.01 |
| PEG Ratio | N/A | 24.01 |
| Price to Sales (TTM) | 2.64 | 1.15 |
| Price to Book (MRQ) | 4.64 | 2.03 |
| Market Capitalization | ||
| Market Capitalization | ₹3.22B | ₹47.94B |
| Enterprise Value | ₹2.46B | ₹58.31B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.01 | 1.40 |
| Enterprise to EBITDA | 44.92 | 11.39 |
| Risk & Other Metrics | ||
| Beta | -1.45 | -0.08 |
| Book Value per Share (MRQ) | ₹46.27 | ₹115.00 |
Financial Statements Comparison: Trident Texofab vs Indo Count
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TTFL | ICIL |
|---|---|---|
| Revenue/Sales | ₹382.06M | ₹10.23B |
| Cost of Goods Sold | ₹328.49M | ₹5.05B |
| Gross Profit | ₹53.58M | ₹5.17B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹14.91M | ₹458.05M |
| EBITDA | ₹18.34M | ₹879.06M |
| Pre-Tax Income | ₹3.83M | ₹156.24M |
| Income Tax | ₹-1.27M | ₹44.22M |
| Net Income (Profit) | ₹5.10M | ₹112.02M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TTFL | ICIL |
|---|---|---|
| Cash & Equivalents | ₹1.09M | ₹1.06B |
| Total Current Assets | ₹737.44M | ₹22.28B |
| Total Current Liabilities | ₹407.50M | ₹13.14B |
| Long-Term Debt | ₹102.71M | ₹4.77B |
| Total Shareholders Equity | ₹472.39M | ₹22.78B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹200.87M | ₹16.22B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TTFL | ICIL |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TTFL | ICIL |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,700 | 228,047 |
| Average Daily Volume (90 Day) | 18,958 | 292,307 |
| Shares Outstanding | 13.56M | 198.05M |
| Float Shares | 5.51M | 76.71M |
| % Held by Insiders | 0.38% | 0.61% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Trident Texofab vs Indo Count
| Metric | TTFL | ICIL |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹2.00 |
| Last 12-Month Dividend Yield | N/A | 0.86% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹2.73 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | ₹0.00 | ₹8.20 |
| Ex-Dividend Date | N/A | Aug 11, 2025 |